Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer

References

• Clogston JD, Patri AK. (2011). Detecting and measuring free gadolinium in nanoparticles for MRI imaging. Methods Mol Biol 697:101–8
   PubMedGoogle Scholar
• Ersoy H, Rybicki FJ. (2007). Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. Journal of Magnetic Resonance Imaging: JMRI 26:1190–7
   PubMed Web of Science ®Google Scholar
• Fisher RE, Siegel BA, Edell SL, et al. (2008). Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nuclear Med 49:899–906
   PubMed Web of Science ®Google Scholar
• Ganta S, Singh A, Patel NR, et al. (2014a). Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res
   PubMed Web of Science ®Google Scholar
• Ganta S, Talekar M, Singh A, et al. (2014b). Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSci Tech
   PubMed Web of Science ®Google Scholar
• Goren D, Horowitz AT, Tzemach D, et al. (2000). Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949–57
   PubMed Web of Science ®Google Scholar
• Grant CW, Karlik S, Florio E. (1989). A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med 11:236–43
   PubMed Web of Science ®Google Scholar
• Joo WD, Visintin I, Mor G. (2013). Targeted cancer therapy – are the days of systemic chemotherapy numbered? Maturitas 76:308–14
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Draper D, Chen CC, et al. (2011). A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569–80
   PubMed Web of Science ®Google Scholar
• Lachman L, Liebermann HA, Kanig JL. (1986). The Theory and practice of industrial pharmacy, Philadelphia: Lea & Febiger
   Google Scholar
• Leamon CP. (2008). Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277–86
   PubMed Web of Science ®Google Scholar
• Leamon CP, Cooper SR, Hardee GE. (2003). Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14:738–47
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, et al. (2002). Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240:95–102
   PubMed Web of Science ®Google Scholar
• Li J, Sausville EA, Klein PJ, et al. (2009). Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49:1467–76
   PubMed Web of Science ®Google Scholar
• Mignogna C, Staibano S, Altieri V, et al. (2006). Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 6:293
   PubMed Web of Science ®Google Scholar
• Muller C, Schibli R, Krenning EP, De Jong M. (2008). Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer. J Nucl Med 49:623–9
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Westrick E, et al. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284–93
   PubMed Web of Science ®Google Scholar
• Penson RT, Oliva E, Skates SJ, et al. (2004). Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98–106
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, et al. (2005). Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–91
   PubMed Web of Science ®Google Scholar
• Rose DP, Connolly JM. (1999). Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83:217–44
   PubMed Web of Science ®Google Scholar
• Ruff P, Vorobiof DA, Jordaan JP, et al. (2009). A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 64:763–8
   PubMed Web of Science ®Google Scholar
• Sadurni N, Solans C, Azemar N, et al. (2005). Studies on the formation of O/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur J Pharm Sci 26:438–45
   PubMed Web of Science ®Google Scholar
• Seiden MV, Swenerton KD, Matulonis U, et al. (2002). A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302–10
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. (2010). Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10:431–7
   PubMed Web of Science ®Google Scholar
• Sudimack J, Lee RJ. (2000). Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147–62
   PubMed Web of Science ®Google Scholar
• Thanos CG, Liu Z, Goddard M, et al. (2003). Enhancing the oral bioavailability of the poorly soluble drug dicumarol with a bioadhesive polymer. J Pharm Sci 92:1677–89
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cernigoi C, Russo A, et al. (1997). Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193–8
   PubMed Web of Science ®Google Scholar